Does Higher Gadolinium Concentration Play a Role in the Morphologic Assessment of Brain Tumors? Results of a Multicenter Intraindividual Crossover Comparison of Gadobutrol versus Gadobenate Dimeglumine (the MERIT Study)

References

1. 1.↵
   1. Colosimo C,
   2. Ruscalleda J,
   3. Korves M,
   4. et al

   . Detection of intracranial metastases: a multi-center, intra-patient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dose. Invest Radiol 2001;36:72–81

   CrossRefPubMed
2. 2.↵
   1. Knopp MV,
   2. Runge VM,
   3. Essig M,
   4. et al

   . Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology 2004;230:55–64

   PubMed
3. 3.↵
   1. Colosimo C,
   2. Knopp MV,
   3. Barreau X,
   4. et al

   . A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours. Neuroradiology 2004;46:655–65

   PubMed
4. 4.↵
   1. Essig M,
   2. Tartaro A,
   3. Tartaglione T,
   4. et al

   . Enhancing lesions of the brain: intra-individual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators. Acad Radiol 2006;13:744–51

   CrossRefPubMed
5. 5.↵
   1. Maravilla KR,
   2. Maldjian JA,
   3. Schmalfuss IM,
   4. et al

   . Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology 2006;240:389–400

   CrossRefPubMed
6. 6.↵
   1. Kuhn MJ,
   2. Picozzi P,
   3. Maldjian JA,
   4. et al

   . Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. J Neurosurg 2007;106:557–66

   CrossRefPubMed
7. 7.↵
   1. Rowley HA,
   2. Scialfa G,
   3. Gao PY,
   4. et al

   . Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. AJNR Am J Neuroradiol 2008;29:1684–91

   Abstract/FREE Full Text
8. 8.↵
   1. Rumboldt Z,
   2. Rowley HA,
   3. Steinberg F,
   4. et al

   . Multicenter, double-blind, randomized, intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 Tesla. J Magn Reson Imaging 2009;29:760–67

   CrossRefPubMed
9. 9.↵
   MultiHance. Summary of product characteristics. http://www.medicines.org.uk/emc/medicine/6132/SPC/multihance/#INDICATIONS. Accessed February 3, 2011
10. 10.↵
    1. Pintaske J,
    2. Martirosian P,
    3. Graf H,
    4. et al

    . Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006;41:213–21. Erratum in Invest Radiol 2006;41:859

    CrossRefPubMed
11. 11.↵
    1. Rohrer M,
    2. Bauer H,
    3. Mintorovitch J,
    4. et al

    . Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005;40:715–24

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Cavagna FM,
    2. Maggioni F,
    3. Castelli PM,
    4. et al

    . Gadolinium chelates with weak binding to serum proteins: a new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 1997;32:780–96

    CrossRefPubMed
13. 13.↵
    1. Giesel FL,
    2. von Tengg-Kobligk H,
    3. Wilkinson ID,
    4. et al

    . Influence of human serum albumin on longitudinal and transverse relaxation rates (R1 and R2) of magnetic resonance contrast agents. Invest Radiol 2006;41:222–28

    CrossRefPubMed
14. 14.↵
    Gadavist (gadobutrol) injection. Bayer HealthCare Pharmaceuticals; March 2011. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=40544. Accessed February 3, 2012
15. 15.↵
    1. Anzalone N,
    2. Gerevini S,
    3. Scotti R,
    4. et al

    . Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine. Acta Radiol 2009;50:933–40

    Abstract/FREE Full Text
16. 16.↵
    1. Kim ES,
    2. Chang JH,
    3. Choi HS,
    4. et al

    . Diagnostic yield of double-dose gadobutrol in the detection of brain metastasis: intraindividual comparison with double-dose gadopentetate dimeglumine. AJNR Am J Neuroradiol 2010;31:1055–58

    Abstract/FREE Full Text
17. 17.↵
    1. Katakami N,
    2. Inaba Y,
    3. Sugata S,
    4. et al

    . Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase II/III study in patients with known or suspected brain metastases. Invest Radiol 2011; 46:411–18
18. 18.↵
    1. Fleiss JL

    . Statistical Methods for Rates and Proportions. 2nd ed. New York: John Wiley & Sons Inc; 1981
19. 19.↵
    1. Kirchin MA,
    2. Runge VM

    . Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 2003;14:426–35

    CrossRefPubMed
20. 20.↵
    1. Laurent S,
    2. Elst LV,
    3. Muller RN

    . Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 2006;1:128–37

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Yuh WT,
    2. Fisher DJ,
    3. Engelken JD,
    4. et al

    . MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 1991;180:485–91

    PubMed
22. 22.↵
    1. Schneider G,
    2. Kirchin MA,
    3. Pirovano G,
    4. et al

    . Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: effect of dose on lesion detection and delineation. J Magn Reson Imaging 2001;14:525–39

    CrossRefPubMed
23. 23.↵
    1. Wollanka H,
    2. Weidenmaier W,
    3. Giersig C

    . NSF after Gadovist exposure: a case report and hypothesis of NSF development. Nephrol Dial Transplant 2009;24:3882–84. Epub 2009 Sep 19

    Abstract/FREE Full Text
24. 24.↵
    1. Elmholdt TR,
    2. Jørgensen B,
    3. Ramsing M,
    4. et al

    . Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol. Nephrol Dial Transplant 2010;3:285–87
25. 25.↵
    1. Anzalone N

    . Comparative studies of different gadolinium agents in brain tumors: differences between gadolinium chelates and their possible influence on imaging features. AJNR Am J Neuroradiol 2010;31:981–82

    FREE Full Text
26. 26.↵
    1. Achenbach M,
    2. Figiel JH,
    3. Burbelko M,
    4. et al

    . Prospective comparison of image quality and diagnostic accuracy of 0.5 molar gadobenate dimeglumine and 1.0 molar gadobutrol in contrast-enhanced run-off magnetic resonance angiography of the lower extremities. J Magn Reson Imaging 2010;32:1166–71

    CrossRefPubMed
27. 27.↵
    1. Grazioli L,
    2. Morana G,
    3. Kirchin MA,
    4. et al

    . Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005;236:166–77

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Morana G,
    2. Grazioli L,
    3. Kirchin MA,
    4. et al

    . Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration. Invest Radiol 2011;46:225–39

    CrossRefPubMed
29. 29.↵
    1. de Haën C,
    2. Cabrini M,
    3. Akhnana L,
    4. et al

    . Gadobenate dimeglumine 0.5M solution for injection (MultiHance): pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 1999;23(suppl 1):S161–68

    CrossRefPubMed
30. 30.↵
    1. Banci L,
    2. Bertini I,
    3. Luchinat C

    . Nuclear and Electron Relaxation. Weinheim, Germany: VCH Verlagsgesellschaft; 1991:138
31. 31.↵
    1. Bültmann E,
    2. Erb G,
    3. Kirchin MA,
    4. et al

    . Intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced MR angiography of the supraaortic vessels at 3 Tesla. Invest Radiol 2008;43:695–702

    CrossRefPubMed
32. 32.↵
    1. Vogler H,
    2. Platzek J,
    3. Schuhmann-Giampieri G,
    4. et al

    . Pre-clinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imaging. Eur J Radiol 1995;21:1–10

    CrossRefPubMed
33. 33.↵
    1. Tombach B,
    2. Heindel W

    . Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol. Eur Radiol 2002;12:1550–56

    CrossRefPubMed
34. 34.↵
    1. Gerretsen SC,
    2. le Maire TF,
    3. Miller S,
    4. et al

    . Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for MR angiography of peripheral arteries. Radiology 2010;255:988–1000

    CrossRefPubMed
35. 35.↵
    1. Schneider G,
    2. Pasowicz M,
    3. Vymazal J,
    4. et al

    . Gadobenate dimeglumine and gadofosveset trisodium for MR angiography of the renal arteries: multicenter intraindividual crossover comparison. AJR Am J Roentgenol 2010;195:476–85

    CrossRefPubMed
36. 36.↵
    1. Martincich L,
    2. Faivre-Pierret M,
    3. Zechmann CM,
    4. et al

    . Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for breast MR imaging (DETECT trial). Radiology 2011;258:396–408

    CrossRefPubMed
37. 37.↵
    1. Heiland S,
    2. Erb G,
    3. Ziegler S,
    4. et al

    . Where contrast agent concentration really matters: a comparison of CT and MRI. Invest Radiol 2010;45:529–37

    CrossRefPubMed